- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Oppenheimer bestätigt "Outperform" für Gain Therapeutics | 4 | Investing.com Deutsch | ||
| 27.05. | Gain Therapeutics stock maintained at Outperform by Oppenheimer | 1 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.05. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Gain Therapeutics presents phase 1b data on Parkinson's drug | 3 | Investing.com | ||
| 11.05. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics übertrifft Verlustprognosen - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 11.05. | Gain Therapeutics GAAP EPS of -$0.13 beats by $0.01 | 2 | Seeking Alpha | ||
| 11.05. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update | 243 | GlobeNewswire (Europe) | BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the... ► Artikel lesen | |
| 24.04. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 26.03. | Gain Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Gain Therapeutics GAAP EPS of -$0.61 beats by $0.03 | 2 | Seeking Alpha | ||
| 18.03. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Gain Therapeutics reports biomarker data from Parkinson's trial | 1 | Investing.com | ||
| 18.03. | Gain Therapeutics legt vielversprechende Biomarker-Daten aus Parkinson-Studie vor | 18 | Investing.com Deutsch | ||
| 18.03. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 03.02. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.01. | Gain Therapeutics reports 81% reduction in Parkinson's biomarker | 13 | Investing.com | ||
| 22.12.25 | Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data | 1 | Investing.com | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAGE LABS | 14,440 | -2,50 % | Roth/MKM initiates BioAge Labs stock coverage with buy rating | ||
| QUINCE THERAPEUTICS | 1,050 | -5,41 % | After rare disease flop, cash-strapped Quince finds salvation in reverse merger | ||
| FRACTYL HEALTH | 0,788 | -2,22 % | Fractyl Health names Mike Zumdahl as market access head | ||
| PRAXIS PRECISION MEDICINES | 258,08 | -23,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,480 | -2,46 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,71 | -0,74 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,690 | +11,67 % | Relay Therapeutics Shares Jump 18% | ||
| COGENT BIOSCIENCES | 32,760 | -6,29 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| QIAGEN | 30,705 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,300 | +9,19 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,505 | -2,16 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 10,690 | -15,89 % | Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer | Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results... ► Artikel lesen | |
| DISC MEDICINE | 68,00 | -5,52 % | Disc Medicine launches expanded access program for bitopertin | ||
| FULCRUM THERAPEUTICS | 3,140 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | ? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik- (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk... ► Artikel lesen |
GAIN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,125 (-6,41 %) liegt der Kurs bei 1,825 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.